Skip to main
GHRS

GHRS Stock Forecast & Price Target

GHRS Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GH Research is poised to have a successful future due to their recent clearances from the FDA and completion of Phase I studies, reaffirming their potential to replicate a primary Phase IIb design and the positive current atmosphere in the psychedelics space. Despite potential concerns over functional unbinding and regulatory decisions for COMP360, GH Research has shown impressive efficacy and a significant sales opportunity, leading to a positive outlook and increased future potential for the company's stock.

Bears say

GH Research is a clinical-stage biopharmaceutical company with a single segment focusing on research and development of mebufotenin therapies for treatment-resistant depression (TRD). While the company has upcoming milestones in the second half of 2026 and a strong financial position, including a current cash balance of $362.7MM, GH Research's lead product candidate, GH001, is only in Phase 2b clinical trials, and the company faces potential challenges with enrollment targets and the need for a psychotherapist during treatment. Furthermore, the company has yet to expand its product candidates into other indications and formulations, and we will only receive updates on these potential developments once GH001's Phase 3 trial is underway.

GHRS has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GH Research PLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GH Research PLC (GHRS) Forecast

Analysts have given GHRS a Buy based on their latest research and market trends.

According to 8 analysts, GHRS has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GH Research PLC (GHRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.